Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Yeun Mi Yim"'
Autor:
William Wong, Yeun Mi Yim, Ashley Kim, Martin Cloutier, Marjolaine Gauthier-Loiselle, Patrick Gagnon-Sanschagrin, Annie Guerin
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0196007 (2018)
Adverse event (AE)-related costs represent an important component of economic models for cancer care. However, since previous studies mostly focused on specific AEs, treatments, or cancer types, limited information is currently available. Therefore,
Externí odkaz:
https://doaj.org/article/04bc6872a69a49b7a5ac97cadecbd1df
Autor:
Olga V. Patterson, Yeun Mi Yim, R. Morlock, Vanessa Stevens, David D. Stenehjem, Aaron W. C. Kamauu, Scott L. DuVall
Publikováno v:
Archives of Dermatological Research. 310:505-513
Available descriptive statistics for patients with metastatic basal cell carcinoma (mBCC) are limited. To describe disease characteristics, treatment patterns, survival outcomes, and prognostic factors of patients with mBCC, we conducted a retrospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faa685c16d3d3cd701aca8c85c70cfcb
https://doi.org/10.1007/s00403-018-1834-8
https://doi.org/10.1007/s00403-018-1834-8
Autor:
Jay Schukman, Arthur Small, Maxine D. Fisher, Jennifer Malin, Rajeshwari S. Punekar, Rakesh Luthra, Barbara L. McAneny, Yeun Mi Yim, Joseph Singer
Publikováno v:
Journal of Oncology Practice. 13:e37-e46
Purpose: The current shift in site of care from community oncology practices to the hospital outpatient department to deliver oncology services may have significant implications for the economic and clinical outcomes of cancer care. Therefore, this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e902ff8acd6f6bd1e953d83a87f4559
https://doi.org/10.1200/jop.2016.012930
https://doi.org/10.1200/jop.2016.012930
Autor:
Daniel Sheinson, Pei-Jung Lin, Ning Wu, Yeun Mi Yim, William Wong, Joshua T. Cohen, Scott D. Ramsey
Publikováno v:
Journal of oncology practice. 15(11)
PURPOSE: The National Comprehensive Cancer Network (NCCN) developed the Evidence Blocks framework to assess the value of oncology regimens. This study characterizes the relationship between real-world costs and NCCN affordability ratings (ARs) for ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41a3f650b14d1fcbb94e704770c84f6d
https://pubmed.ncbi.nlm.nih.gov/31513478
https://pubmed.ncbi.nlm.nih.gov/31513478
Autor:
Sarang Abhyankar, Vernon F. Schabert, P. Donga, Chun-Lan Chang, Yeun Mi Yim, Carolina M. Reyes, J. Munakata
Publikováno v:
Melanoma Research. 25:312-320
Recent advances have increased treatment options for, and improved clinical outcomes in, metastatic melanoma (mM). Using a large claims database, this retrospective study compared healthcare and adverse event (AE) costs in a US managed care populatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e009aa02851bc444daf6f3411f1297a5
https://doi.org/10.1097/cmr.0000000000000159
https://doi.org/10.1097/cmr.0000000000000159
Autor:
Sarang Abhyankar, Charles Ayas, Yeun Mi Yim, Annie Guerin, Eric Q. Wu, Carolina Reyes, Geoffrey T. Gibney, Geneviève Gauthier, Philip Galebach
Publikováno v:
Cancer Medicine
Brain metastases are a common and serious complication among patients with metastatic melanoma. The selective BRAF inhibitor vemurafenib has demonstrated clinical efficacy in patients with BRAF V600E-mutant melanoma brain metastases (MBM). We examine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9341ee8335f36c728facb8c99975b513
http://europepmc.org/articles/PMC4559032
http://europepmc.org/articles/PMC4559032
Publikováno v:
Journal of Clinical Oncology. 37:e18119-e18119
e18119 Background: Prior studies suggest cancer patients with Medicaid may have worse outcomes, however there is limited understanding on the drivers behind these observations. This study aimed to describe the association between insurance type with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f8dee75a7f909aa18a7edcf94370d5f
https://doi.org/10.1200/jco.2019.37.15_suppl.e18119
https://doi.org/10.1200/jco.2019.37.15_suppl.e18119
Publikováno v:
Journal of Medical Economics. 14:542-552
To compare the health care costs of patients with metastatic colorectal cancer (mCRC) who received second-line treatment with Avastin (bevacizumab) versus Erbitux (cetuximab), from the third-party payer's perspective.Patients with mCRC were selected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c603fd0272e70b8fa7983b736630321
https://doi.org/10.3111/13696998.2011.596600
https://doi.org/10.3111/13696998.2011.596600
Autor:
Pei-Jung Lin, Scott D. Ramsey, William Wong, Daniel Sheinson, Joshua T. Cohen, Ning Wu, Yeun Mi Yim
Publikováno v:
Journal of Clinical Oncology. 36:6512-6512
6512Background: The NCCN EB are designed to provide AR on the overall cost of drug treatments (tx), including medication, administration, supportive care, side effect management and hospitalization...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e27d9c4cf5ffdb13d98cbb9062280977
https://doi.org/10.1200/jco.2018.36.15_suppl.6512
https://doi.org/10.1200/jco.2018.36.15_suppl.6512
Autor:
Yeun Mi Yim, Ashley Kim, William Wong, Annie Guerin, Patrick Gagnon-Sanschagrin, Marjolaine Gauthier-Loiselle, Martin Cloutier
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0196007 (2018)
PLoS ONE
PLoS ONE
Adverse event (AE)-related costs represent an important component of economic models for cancer care. However, since previous studies mostly focused on specific AEs, treatments, or cancer types, limited information is currently available. Therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdc48517f4c3fb53eb621a264131b838
https://doi.org/10.1371/journal.pone.0196007
https://doi.org/10.1371/journal.pone.0196007